Primjena nanoterapeutika u liječenju tumora

Stručni rad - Stručni rad

• Autor: Vesna Valentić
• Autor: Mario Jug
• Autorova ustanova: Sveučilište u Zagrebu; Farmaceutsko-biokemijski fakultet; (Zavod za farmaceutsku tehnologiju)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Farmacija; Farmacija

Sažetak (engleski)

Nanopharmaceuticals ( 1 -100 nm) represent an opportunity of improving the
cancer treatment. Due to its unique characteristics, nanopharmaceuticals have many
advantages over conventional chemotherapy. The most important advantage is the
potential of targeted delivery of drugs to the tumor tissue resulting in lower systemic
toxicity which is the most prominent disadvantage of conventional chemocherapy.
Nanoparticles can passively reach the tumor tissue through the leaky vasculature
surrounding the tumor due to the increased permeability and retention effect. ln
active targeting, targeting ligands are attached at the surface of the nanocarrier for
binding to appropriate receptors overexpressed by the tumor cells or tumor vasculature
and not expressed by the normal cells. Stimuli-sensitive nanocarriers respond to
physical, chemical, or biological stimuli chat promote the release of the drug. Multifunctional
nanocarriers have several useful properties. Theranoscics are an emerging
subset of multifunctional nanocarriers which provide both the diagnosis and treatment
with the same nanoformulation. Various types of nanopharmaceuticals have
been used in clinical cancer treatment, including drug conjugates, lipid or polymerbased
nanocarriers and inorganic nanoparticles. At the present, the most successful
nanomedicine therapeutics in clinical cancer care are drug conjugates. Most clinically
available nanocarrier-based cancer therapeutics are passively targeted first-generation
nanomedicine drugs. In order to reach the target site, nanoparticles have to avoid
degradation by the mononuclear phagocyte system and renal filtration, extravasate
into tumor compartment, travel through the tumor stroma against high interstitial
fluid pressure gradients, and then interact with target cells or release the drug payload
for pharmacological effect. Therefore, for optimal delivery it is necessary to optimize
not only the physicochemical properties of the nanoparticles, but also to consider the
tumor microenvironment.

• Ključne riječi (hrvatski): nanofarmaceutici; tumori; nanoterapeutici
• Jezik: hrvatski
• Vrsta publikacije: Stručni rad - Stručni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran - domaća recenzija
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Farmaceutski glasnik
• Brojčani podaci: vol. 71, br. 11, str. 599-613
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:298083
• Datum objave publikacije: 2015
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2021-02-17 12:34:31